Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) have been assigned an average recommendation of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a hold recommendation. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $10.80.

Several equities analysts have commented on the company. Wedbush lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating and lowered their price target for the company from $13.00 to $8.00 in a report on Thursday, May 22nd. JMP Securities reissued a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Citizens Jmp lowered Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Stifel Nicolaus cut Vigil Neuroscience from a “buy” rating to a “hold” rating and lowered their price target for the company from $11.00 to $8.00 in a research report on Wednesday, May 28th. Finally, Mizuho cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VIGL. Cubist Systematic Strategies LLC increased its position in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares during the period. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the 4th quarter valued at about $83,000. Barclays PLC grew its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after buying an additional 19,436 shares during the period. Northern Trust Corp raised its stake in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after buying an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after buying an additional 49,000 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL opened at $7.92 on Tuesday. The firm has a market cap of $369.63 million, a price-to-earnings ratio of -3.86 and a beta of 3.43. The business has a fifty day simple moving average of $4.67 and a 200 day simple moving average of $2.98. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. On average, sell-side analysts forecast that Vigil Neuroscience will post -2.07 EPS for the current year.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.